论文部分内容阅读
目的观察尿苷二磷酸葡萄糖醛酸转移酶1A1*28(UGT1A1*28)基因多态性与伊立替康CPT11二线治疗小细胞肺癌患者临床疗效和毒副反应的相关性。方法 62例小细胞肺癌患者,给予二线伊立替康化疗,化疗前行UGT1A1*28的基因多态性检测。结果突变型患者3~4级腹泻和中性粒细胞减少的发生率明显高于野生型(P<0.05),两者有效率、疾病控制率、疾病进展时间、生存时间方面比较差异无统计学意义(P>0.05)。结论 UGT1A1*28基因多态性与伊立替康二线治疗小细胞肺癌发生严重的腹泻和中性粒细胞减少有关,但与其临床疗效无关。
Objective To investigate the relationship between uridine diphosphate glucuronyl transferase 1A1 * 28 (UGT1A1 * 28) gene polymorphism and the efficacy and toxicity of irinotecan CPT11 second-line therapy in patients with small cell lung cancer. Methods 62 patients with small cell lung cancer were treated with second-line irinotecan chemotherapy and UGT1A1 * 28 gene polymorphism before chemotherapy. Results The incidence of grade 3-4 diarrhea and neutropenia were significantly higher in mutant patients than in wild type (P <0.05). There was no significant difference in the effective rate, disease control rate, disease progression time and survival time Significance (P> 0.05). Conclusion The UGT1A1 * 28 gene polymorphism is associated with serious diarrhea and neutropenia in irinotecan second-line treatment of small cell lung cancer, but not with clinical efficacy.